Pays: Irlande
Langue: anglais
Source: HPRA (Health Products Regulatory Authority)
Milbemycin oxime; Praziquantel
Krka, d.d., Novo mesto
QP54AB51
Milbemycin oxime; Praziquantel
2.5,25 mg/tablet
Film-coated tablet
POM: Prescription Only Medicine as defined in relevant national legislation
milbemycin oxime, combinations
Authorised
2021-09-17
Health Products Regulatory Authority 17 September 2021 CRN009WHS Page 1 of 5 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Amcofen 2.5 mg/25 mg film-coated tablets for small dogs and puppies weighing at least 0.5 kg 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains: ACTIVE SUBSTANCES: Milbemycin oxime 2.5 mg Praziquantel 25.0 mg EXCIPIENTS: For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Film-coated tablet. Pale yellowish brown, oval, biconvex, mottled, film coated tablets, scored on one side. The tablets can be divided into equal halves. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs (small dogs and puppies). 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Treatment of mixed infections by adult cestodes and nematodes of the following species: - Cestodes: _Dipylidium caninum_ _Taenia_ spp. _Echinococcus_ spp. _Mesocestoides_ spp. - Nematodes: _Ancylostoma caninum_ _Toxocara canis_ _Toxascaris leonina_ _Trichuris vulpis_ _Crenosoma vulpis _(Reduction of the level of infection) _Angiostrongylus vasorum _(Reduction of the level of infection by immature adult (L5) and adult parasite stages; see specific treatment and disease prevention schedules under section 4.9 Amounts to be administered and administration route). _Thelazia callipaeda_ (see specific treatment schedule under section 4.9 Amounts to be administered and administration route). The product can also be used in the prevention of heartworm disease (_Dirofilaria immitis_), if concomitant treatment against cestodes is indicated. 4.3 CONTRAINDICATIONS Do not use in puppies of less than 2 weeks of age and/or weighing less than 0.5 kg. Do not use in cases of hypersensitivity to the active substances or to any of the excipients. See also section 4.5 Special precautions for use. Health Products Regulatory Authority 17 September 2021 CRN009WHS Page 2 of 5 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES Parasite resistance to any particular class of anthelmintic may develop followi Lire le document complet